Literature DB >> 20407401

High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade.

Tamara L Floyd, Steven B Orr, Shana M Coley, Samantha S Hanna, Maylene E Wagener, Allan D Kirk, Christian P Larsen, Mandy L Ford.   

Abstract

BACKGROUND: Blockade of costimulatory molecules is a potent method of inducing long-term graft survival. We have previously addressed the issue of donor-reactive T-cell precursor frequency on relative costimulation dependence and found that the presence of a high precursor frequency of donor-reactive CD8 T cells resulted in costimulation blockade-resistant graft rejection, whereas the presence of a low-frequency donor-reactive population did not. To address the mechanisms by which high-frequency T cells obviated the requirement for costimulation, we asked whether a low-frequency population responding concomitantly with a high-frequency response also demonstrated costimulation independence.
METHODS: A model system was established in which B6 mice containing a low frequency of anti-membrane bound chicken ovalbumin (mOVA) responders and a high frequency of anti-BALB/c responders received a skin graft from B6.mOVAxBALB/c F1 donors in the presence or absence of cytotoxic T-lymphocyte antigen-4 Ig/anti-CD154 costimulatory blockade.
RESULTS: The results revealed that in the presence of costimulation blockade, high-frequency anti-BALB/c T cells augmented the effector activity of low-frequency anti-mOVA T cells, but it did not enhance the accumulation of anti-mOVA T cells capable of mediating graft rejection.
CONCLUSIONS: These results demonstrate that both antigen-specific and antigen-independent factors contribute to the relative costimulation independence of high-frequency T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407401      PMCID: PMC2935314          DOI: 10.1097/TP.0b013e3181df53dc

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  34 in total

1.  Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.

Authors:  M A Williams; J Trambley; J Ha; A B Adams; M M Durham; P Rees; S R Cowan; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

2.  Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.

Authors:  J Trambley; A W Bingaman; A Lin; E T Elwood; S Y Waitze; J Ha; M M Durham; M Corbascio; S R Cowan; T C Pearson; C P Larsen
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway.

Authors:  Z Guo; L Meng; O Kim; J Wang; J Hart; G He; M L Alegre; J R Thistlethwaite; T C Pearson; C P Larsen; K A Newell
Journal:  Transplantation       Date:  2001-05-15       Impact factor: 4.939

4.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

Review 5.  Polyspecificity of T cell and B cell receptor recognition.

Authors:  Kai W Wucherpfennig; Paul M Allen; Franco Celada; Irun R Cohen; Rob De Boer; K Christopher Garcia; Byron Goldstein; Ralph Greenspan; David Hafler; Philip Hodgkin; Erik S Huseby; David C Krakauer; David Nemazee; Alan S Perelson; Clemencia Pinilla; Roland K Strong; Eli E Sercarz
Journal:  Semin Immunol       Date:  2007-03-29       Impact factor: 11.130

6.  Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire.

Authors:  R Obst; C Münz; S Stevanović; H G Rammensee
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

7.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Authors:  C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson
Journal:  Nature       Date:  1996-05-30       Impact factor: 49.962

8.  Estimating the precursor frequency of naive antigen-specific CD8 T cells.

Authors:  Joseph N Blattman; Rustom Antia; David J D Sourdive; Xiaochi Wang; Susan M Kaech; Kaja Murali-Krishna; John D Altman; Rafi Ahmed
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

9.  Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.

Authors:  M Har-Noy; M Zeira; L Weiss; S Slavin
Journal:  Leuk Res       Date:  2008-06-18       Impact factor: 3.156

10.  Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors.

Authors:  K F Lindahl; D B Wilson
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Update on CD40 and CD154 blockade in transplant models.

Authors:  Tianshu Zhang; Richard N Pierson; Agnes M Azimzadeh
Journal:  Immunotherapy       Date:  2015-08-13       Impact factor: 4.196

2.  Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.

Authors:  Channakeshava S Umeshappa; Roopa H Nanjundappa; Yufeng Xie; Andrew Freywald; Qingyong Xu; Jim Xiang
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

3.  CD28 family and chronic rejection: "to belatacept...And beyond!".

Authors:  Marcos V Silva; Juliana R Machado; Laura P Rocha; Lúcio R Castellano; Marlene A Reis; Rosana R M Corrêa
Journal:  J Transplant       Date:  2012-06-07

4.  Alloimmunity But Not Viral Immunity Promotes Allograft Loss in a Mouse Model of Polyomavirus-Associated Allograft Injury.

Authors:  Steven C Kim; Jun Wang; Ying Dong; David V Mathews; Joshua A Albrecht; Cynthia P Breeden; Alton B Farris; Aron E Lukacher; Mandy L Ford; Kenneth A Newell; Andrew B Adams
Journal:  Transplant Direct       Date:  2017-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.